Lanacordin Pediátrico

Digoxin, the active ingredient in Lanacordin Pediátrico, is a cardiac glycoside presented as an oral formulation for oral use. It is employed to improve cardiac contractility in heart failure and to control ventricular rate in atrial fibrillation, particularly in pediatric patients.

GNH USA supplies Lanacordin Pediátrico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. This includes compliance with EU GMP guidelines and traceability throughout the supply chain.

Digoxin acts on the cardiac conduction system and myocardial contractility, providing therapeutic benefit in specific cardiovascular conditions. - Heart failure: improves cardiac output and reduces symptoms of congestion. - Atrial fibrillation (rate control): slows atrioventricular nodal conduction to achieve ventricular rate control. - Atrial flutter (rate control): reduces ventricular response by decreasing AV nodal transmission. - Supraventricular tachycardia: helps control heart rate when other agents are unsuitable.

Digoxin may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may be transient. - Diarrhea: loose stools that can lead to dehydration. - Fatigue or weakness: reduced energy levels and muscle strength. - Blurred vision or color disturbances: visual changes such as yellow‑green halos.

Serious or Rare Side Effects: - Cardiac arrhythmias including ventricular tachycardia: potentially life‑threatening rhythm disturbances. - Severe bradycardia or AV block: markedly slowed heart rate or conduction block. - Hyperkalemia: elevated serum potassium that can exacerbate toxicity. - Allergic reactions such as rash or anaphylaxis: immune‑mediated responses requiring immediate care.

When prescribing digoxin, clinicians should observe several safety measures to minimize toxicity and ensure therapeutic effectiveness. - Monitor serum digoxin levels: adjust dose based on therapeutic range. - Assess renal function: impaired clearance increases risk of accumulation. - Check electrolytes, especially potassium and magnesium: abnormalities heighten toxicity. - Use caution in elderly patients: age‑related pharmacokinetic changes may require lower doses. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Digoxin interacts with several medicines; awareness of these relationships helps avoid adverse events.

Major Interactions (Avoid): - Amiodarone: markedly increases digoxin concentration. - Quinidine: potentiates digoxin effect and toxicity. - Verapamil: raises digoxin levels and may cause bradyarrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): can cause electrolyte shifts that enhance toxicity. - ACE inhibitors: may increase digoxin levels modestly. - NSAIDs: may reduce renal clearance and elevate serum concentrations.